Deal activity in the life sciences sector faced a number of challenging headwinds in 2022. Global macroeconomic turbulence, capital market uncertainty and an increasingly difficult funding environment all conspired to suppress M&A, licensing and collaborative R&D deal volumes over the course of the year.